TYO:4599

2 stories mentioning TYO:4599Updated 19m ago

Every FINWIRES story that references TYO:4599, newest first.

StemRIM to Register Russian Patent of Drug Candidate for Fatty Liver Disease

StemRIM (TYO:4599) will soon register its medical use patent in Russia for its regeneration-inducing drug candidate for the treatment of fatty liver and non-alcoholic steatohepatitis.The Redasemtide patent, jointly filed with Osaka University and Niigata University, is intended to expand the drug's indications and secure development potential in Russia, according to a Tokyo bourse filing on Tuesday.Fatty liver and NASH, which can progress to cirrhosis or liver cancer, lack effective drug treatments and are expected to increase with rising obesity and diabetes rates, the statement said.

TYO:4599

Asia62d ago

StemRIM Finishes Enrollment in Phase 1/2 Redasemtide Study

StemRIM (TYO:4599) said it has completed patient enrollment in a Phase 1/2 investigator-initiated clinical trial of its regenerative medicine candidate redasemtide for ischemic cardiomyopathy, according to a Wednesday filing on the Tokyo Stock Exchange.The trial, conducted at five institutions led by Osaka University Hospital, enrolled 14 patients undergoing coronary artery bypass grafting, with participants receiving redasemtide or a placebo over five days.The primary objective is to evaluate the drug's safety and tolerability, while efficacy will be assessed through cardiac function tests conducted 52 weeks after administration.StemRIM said the enrollment was lower than the initially planned 20 patients, but deemed sufficient to evaluate the primary endpoints based on the overall progress of the trial.

TYO:4599

Track with the FINWIRES app suite

FolioX

Track TYO:4599 in your portfolio

WheelAI

Analyze TYO:4599 options with the wheel strategy

StockInsider

See market sentiment on TYO:4599